R&D channel feed

Af­ter Phase 3 win, Ar­row­head­'s RNAi chas­es Io­n­is to mar­ket en­try in rare ge­net­ic dis­or­der

Last year

Take­da out­lines mid-stage nar­colep­sy da­ta that prompt­ed 'rapid' move in­to Phase 3

Last year

Cari­bou says par­tial HLA match­ing will im­prove dura­bil­i­ty of re­sponse to cell ther­a­py 

Last year

Ex­clu­sive: Iso­tope short­age forces pause of Bris­tol My­ers Phase 3 ra­dio­phar­ma­ceu­ti­cal tri­al

Last year
Pharma
Manufacturing

A small group of melanoma pa­tients may need far less im­munother­a­py with surgery, study sug­gests  

Last year

Up­dat­ed: With a promis­ing new Keytru­da con­tender, Sum­mit pre­pares to spar with Mer­ck

Last year
China
Pharma

Dai­ichi Sankyo, As­traZeneca say En­her­tu works bet­ter than chemo in cer­tain breast can­cer pa­tients

Last year

As­traZeneca, J&J share new da­ta in bids to ex­pand reach of lung can­cer drugs

Last year

GSK plots Blenrep’s re­turn with more da­ta on its ADC for mul­ti­ple myelo­ma

Last year
Pharma

In­tel­lia plots Phase 3 study and a 2026 FDA sub­mis­sion af­ter CRISPR ther­a­py cuts swelling at­tacks by 98%

Last year
Cell/Gene Tx

Gen­Fleet high­lights Phase 2 da­ta on KRAS/EGFR com­bo in lung can­cer 

Last year
China

BMS de­tails con­fir­ma­to­ry tri­al win for KRAS in­hibitor Kraza­ti

Last year

Io­vance's TIL ther­a­py plus Keytru­da show durable treat­ment ef­fect in melanoma, but ac­cess re­mains a ques­tion

Last year
Cell/Gene Tx

Im­muno­core un­veils ear­ly-stage da­ta of skin can­cer treat­ment that led it to start Phase 3 tri­al

Last year

'In­vis­i­ble hand' of in­her­it­ed ge­net­ics can dri­ve can­cer risk, new study sug­gests

Last year

#AS­CO24: No­var­tis' new CML treat­ment tops old­er drugs, in­clud­ing Gleevec, in Phase 3 tri­al

Last year
Pharma

#AS­CO24: Gilead presents more da­ta on failed Trodelvy lung can­cer study

Last year
Pharma

Io­n­is out­lines Phase 3 da­ta for rare dis­ease drug, preps for an­oth­er po­ten­tial launch

Last year

Ul­tragenyx touts Phase 3 win for gene ther­a­py in rare glyco­gen stor­age dis­or­der

Last year
Cell/Gene Tx

Gilead’s block­buster ADC Trodelvy fails blad­der can­cer con­fir­ma­to­ry study

Last year
Pharma
FDA+

Sum­mit Ther­a­peu­tics touts a rare tri­umph over Keytru­da in lung can­cer from a Chi­na-on­ly Phase 3 study

Last year

The bio­phar­ma news we’re pay­ing at­ten­tion to at AS­CO

Last year

No­var­tis ends de­vel­op­ment of KRAS drug, cit­ing 'in­creas­ing op­tions avail­able'

Last year
Pharma

Flush with cash, No­vo Nordisk Foun­da­tion now plans to rein­vest some GLP-1 prof­its in­to re­gen­er­a­tive med­i­cines

Last year
Cell/Gene Tx
First page Previous page 42434445464748 Next page Last page
A service from the Financial Times